Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
RESEARCH TOOLSreports
Holding AUTL?
Track your performance easily
AUTL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.69 - $7.45
Previous Close$2.98
Volume523.12K
Average Volume (3M)1.40M
Market Cap
$835.61M
Enterprise Value$137.12M
Total Cash (Recent Filing)$705.94M
Total Debt (Recent Filing)$50.02M
Price to Earnings (P/E)―
Beta2.64
Next Earnings
Mar 11, 2025EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding266,121,689
10 Day Avg. Volume2,681,228
30 Day Avg. Volume1,403,238
Standard Deviation0.24
R-Squared0.19
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.56
Price to Sales (P/S)76.85
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.95
Enterprise Value/Gross Profit80.75
Enterprise Value/Ebitda-1.11
Forecast
1Y Price Target
$10.32Price Target Upside228.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Autolus Therapeutics News
PremiumCompany Announcements
Autolus Therapeutics Q3 2024 Financial Update and FDA ApprovalOwnership Overview
― Insiders
14.85% Mutual Funds
42.25% Other Institutional Investors
42.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Autolus Therapeutics Plc lowest stock price was $2.69 and its highest was $7.45 in the past 12 months.
What is Autolus Therapeutics Plc’s market cap?
Currently, no data Available
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is Mar 11, 2025 which is in 105 days.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Nov 12, 2024. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.214 by -$0.096.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -$0.21.
How many shares outstanding does Autolus Therapeutics Plc have?
Autolus Therapeutics Plc has 266,121,700 shares outstanding.
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.214. Following the earnings report the stock price went down -5.128%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Among the largest hedge funds holding Autolus Therapeutics Plc’s share is Blackstone Inc.. It holds Autolus Therapeutics Plc’s shares valued at 74M.
---
Autolus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.32 (228.66% Upside)
$10.32 (228.66% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 668.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 4.3%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.91%
12-Months-Change
Fundamentals
Return on Equity
-82.20%
Trailing 12-Months
Asset Growth
103.77%
Trailing 12-Months
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
---
AUTL Company Deck
---
AUTL Earnings Call
Q3 2024
0:00 / 0:00
---
AUTL Stock 12 Month Forecast
Average Price Target
$10.32
▲(228.66% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Bluebird Bio
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering AUTL
1 Year
---